CAMBRIDGE, Mass., Oct. 16, 2017 /PRNewswire/ -- Boston Biomedical, Inc., an industry leader in the development of next-generation cancer therapeutics, today announced the appointment of Edgar Braendle, M.D., Ph.D., to Executive Vice President, Head of Research and Development and Chief Medical Officer. Dr. Braendle will lead the company's discovery research and clinical strategies.
"I am truly excited to join Boston Biomedical at this important juncture to further advance the company's mission to develop innovative cancer therapies that address current treatment challenges of resistance, recurrence and metastasis," said Dr. Braendle. "I look forward to working with the company's talented teams to accelerate and expand the company's broad pipeline and guide its late-stage clinical studies."
Dr. Braendle previously served as President and CEO of ARUP Laboratories, a national clinical and anatomic pathology reference laboratory. Prior to this, he spent more than a decade at Novartis Pharmaceutical Corporation, where he served as Senior Vice President and Global Head of Companion Diagnostics where he led the company's precision medicine approach, delivering complementary and companion diagnostics for Novartis Medicines. In an earlier role as Vice President, Global Head of Oncology Biologics, Dr. Braendle led the development of oncology biologics in early to late stages, successfully filing eight investigational new drug applications.
Dr. Braendle joins an expanding leadership team, including Ms. Dee Mahoney, who was recently appointed as the company's Senior Vice President and Chief Commercial Officer. Ms. Mahoney brings more than 28 years of sales and marketing experience in the bio-pharmaceutical industry in roles ranging from field sales to executive commercial leadership. As Boston Biomedical's Chief Commercial Officer, Ms. Mahoney will lead the commercialization of the company's first-in-class cancer stemness inhibitors, cancer vaccine compounds and other oncology assets in development for the North American market.
Prior to joining Boston Biomedical, Ms. Mahoney was Co-Founder and President of DMH BioPharm Advisors, a boutique management-consulting firm. In this role, Ms. Mahoney partnered with bio-pharmaceutical companies to maximize the effectiveness of commercial strategies and reduce the risk of regulatory non-compliance. Previously, Ms. Mahoney spent 20 years at Pfizer, culminating in the role of Senior Vice President and General Manager of Pfizer's U.S. Specialty Products Business Unit, where she was responsible for the commercial operations and a $2.5 billion portfolio of oncology, anti-infective, HIV, ophthalmology and endocrine care products.
Dr. Braendle and Ms. Mahoney will report to Patricia S. Andrews, Chief Executive Officer.
"We are delighted to have Edgar and Dee join the Boston Biomedical leadership team. Their deep experience in creating and leading highly successful organizations will be of great value to us as we build our research and development platform and commercial capabilities to drive advancement of our novel assets," said Ms. Andrews.
About Boston Biomedical, Inc. Boston Biomedical, Inc. was founded in November 2006 and is a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., a top-ten listed pharmaceutical company in Japan operating globally in major pharmaceutical markets.
Boston Biomedical's mission is to develop the next generation of cancer therapeutics by creating drugs designed to target cancer stemness pathways. Boston Biomedical's innovation in drug discovery has received a number of recognitions and awards in the U.S., including the Frost & Sullivan 2010 North American Drug Discovery Technology Innovation of the Year Award, the National Cancer Institute cancer stem cell initiative grant award in 2010, and the 2011 Biotech Pioneer Award at the Alexandria Oncology Summit. The company also received the "Company To Watch" award in the 10th Annual Team Massachusetts Economic Impact Awards in 2013. Boston Biomedical is headquartered in Cambridge, Massachusetts, USA.
Disclaimer Regarding Forward-Looking Statements The forward-looking statements in this press release are based on management's assumptions and beliefs in light of information presently available, and involve both known and unknown risks and uncertainties. Any forward looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice.
For general inquiries: Boston Biomedical, Inc. 617-674-6800